 Pacira BioSciences Inc NASDAQ: PCRX has announced topline results from its Phase 3 STRIDE study evaluating Exparel administered as combined sciatic in popliteal fossa and saphenous in adductor canal nerve blocks in patients after lower extremity surgeries. The trial did not meet the primary endpoint of statistical significance in pain reduction from 0 to 96 hours for Exparel versus bupivacaine HCl. 